Drug developers Akebia Therapeutics and MediWound banked a combined $170 million in their Wall Street debuts, stacking cash for their lead programs and taking advantage of a banner quarter for biotech IPOs.

…read more

Source: Biotechs bag $170M in IPO cash as a booming quarter winds down